Skip to main content
SpringerLink
Log in
Book cover

Molecular Mechanisms of Spondyloarthropathies pp 1–16Cite as

Clinical Assessment in the Spondyloarthropathies

  • Chapter

Part of the book series: Advances in Experimental Medicine and Biology ((volume 649))

Abstract

In order to measure disease activity, progression and response to therapy, it is important to use accurate, reliable and feasible outcome measures that can ideally be used in longitudinal cohorts, clinical trials and clinical practice.

With emerging therapies, the focus on the methodology of outcome assessment has increased to ensure that discriminant and responsive instruments are used.

This chapter reviews available measures of three major areas of disease impact in the spondyloarthropathies (disease activity, structural damage and functioning) and discusses the relevance for use in clinical practice. First, the outcome measures available for the assessment of different domains in ankylosing spondylitis, composite-indices and response criteria for use in clinical trials and clinical practice in ankylosing spondylitis are discussed. Secondly, the performance of these in psoriatic arthritis and more disease-specific instruments in psoriatic arthritis are discussed.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dougados M, van der Linden S, Juhlin R et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34(10):1218–1227.

    Article  PubMed  CAS  Google Scholar 

  2. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. ann Rheum Dis 2005; 64(Suppl 2):ii3–8.

    Article  PubMed  Google Scholar 

  3. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27(4):361–368.

    Article  PubMed  Google Scholar 

  4. Boers M, Brooks P, Strand CV et al. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998; 25(2):198–199.

    PubMed  CAS  Google Scholar 

  5. Kavanaugh A, Cassell S. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep 2005; 7(3):195–200.

    Article  PubMed  Google Scholar 

  6. Rigby AS, Silman AJ. Outcome assessment in clinical trials of ankylosing spondylitis. Br J Rheumatol 1991; 30(5):321–322.

    Article  PubMed  CAS  Google Scholar 

  7. van der Heijde D, Bellamy N, Calin A et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in ankylosing spondylitis working group. R Rheumatol 1997; 24(11):2225–2229.

    Google Scholar 

  8. van der Heijde D, Calin A, Dougados M et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS working group. Assessments in ankylosing spondylitis. J Rheumatol 1999; 26(4):951–954.

    PubMed  Google Scholar 

  9. Rudwaleit M, Metter A, Listing J et al. Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006; 54(2):569–578.

    Article  PubMed  Google Scholar 

  10. Balint PV, Kane D, Wilson H et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61(10):905–910.

    Article  PubMed  CAS  Google Scholar 

  11. Mander M, Simpson JM, McLellan A et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46(3):197–202.

    Article  PubMed  CAS  Google Scholar 

  12. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359(9313):1187–1193.

    Article  PubMed  CAS  Google Scholar 

  13. Gladman DD, Cook RJ, Schentag C et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. J Rheumatol 2004; 31(6):1126–1131.

    PubMed  Google Scholar 

  14. Maksymowych WP, Mallon C, Richardson R et al. Development and validation of the edmonton ankylosing spondylitis metrology index. Arthritis Rheum 2006; 55(4):575–582.

    Article  PubMed  Google Scholar 

  15. Viitanen JV, Kautiainen H, Suni J et al. The relative value of spinal and thoracic mobility measurements in ankylosing spondylitis. Scand J Rheumatol 1995; 24(2):94–97.

    Article  PubMed  CAS  Google Scholar 

  16. Heuft-Dorenbosch L, Vosse D, Landewe R et al. Measurement of spinal mobility in ankylosing spondylitis: comparison of occiput-to-wall and tragus-to-wall distance. J Rheumatol 2004; 31(9):1779–1784.

    PubMed  Google Scholar 

  17. Schober P. The lumbar vertebral column and backache. Munch Med Wschr 1937; 84:336.

    Google Scholar 

  18. Macrae IF, Wright V. Measurement of back movement. Ann Rheum Dis 1969; 28(6):584–589.

    Article  PubMed  CAS  Google Scholar 

  19. Moll JM, Wright V. Normal range of spinal mobility. An objective clinical study. Ann Rheum Dis 1971; 30(4):381–386.

    Article  PubMed  CAS  Google Scholar 

  20. Moll JM, Wright V. The pattern of chest and spinal mobility in ankylosing spondylitis. An objective clinical study of 106 patients. Rheumatol Rehabil 1973; 12(3):115–134.

    Article  PubMed  CAS  Google Scholar 

  21. Viitanen JV, Heikkila S, Kokko ML et al. Clinical assessment of spinal mobility measurements in ankylosing spondylitis: a compact set for follow-up and trials? Clin Rheumatol 2000; 19(2):131–137.

    Article  PubMed  CAS  Google Scholar 

  22. Heikkila S, Viitanen JV, Kautiainen H et al. Sensitivity to change of mobility tests: effect of short term intensive physiotherapy and exercise on spinal, hip and shoulder measurements in spondyloarthropathy. J Rheumatol 2000; 27(5):1251–1256.

    PubMed  CAS  Google Scholar 

  23. van der Heijde D, Dijkmans B, Geusens P et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52(2):582–591.

    Article  PubMed  Google Scholar 

  24. Auleley GR, Benbouazza K, Spoorenberg A et al. Evaluation of the smallest detectable difference in outcome or process variables in ankylosing spondylitis. Arthritis Rheum 2002; 47(6):582–587.

    Article  PubMed  Google Scholar 

  25. Jauregui E, Conner-Spady B, Russell AS et al. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. J Rheumatol 2004; 31(12):2422–2428.

    PubMed  Google Scholar 

  26. Brandt J, Listing J, Sieper J et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004; 63(11):1438–1444.

    Article  PubMed  CAS  Google Scholar 

  27. Kruithof E, Van den Bosch F, Bacten D et al. Repeated infusions in infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002; 61(3):207–212.

    Article  PubMed  CAS  Google Scholar 

  28. Breban M, Vignon E, Claudepierre P et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002; 41(11):1280–1285.

    Article  CAS  Google Scholar 

  29. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. J Rheumatol 1994; 21(12):2281–2285.

    PubMed  CAS  Google Scholar 

  30. Dougados M, Gueguen A, Nakache JP et al. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988; 15(2):302–307.

    PubMed  CAS  Google Scholar 

  31. Ruof J, Stucki G. Comparison of the dougados functional index and the bath ankylosing spondylitis functional index. A literature review. J Rheumatol 1999; 26(4):955–960.

    PubMed  CAS  Google Scholar 

  32. Helliwell PS, Marzo-Ortega H, Tennant A. Comparison of a disease-specific and a generic instrument for measuring health-related quality of life in ankylosing spondylitis. Arthritis Rheum 2002; 46(11):3098.

    Article  PubMed  Google Scholar 

  33. Doward LC, Spoorenberg A, Cook SA et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62(1):20–26.

    Article  PubMed  CAS  Google Scholar 

  34. Wanders AJ, Landewe RB, Spoorenberg A et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004; 50(8):2622–2632.

    Article  PubMed  Google Scholar 

  35. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21(12):2286–2291.

    PubMed  CAS  Google Scholar 

  36. Calin A, Nakache JP, Gueguen A et al. Defining disease activity in ankylosing spondylitis: Is a combination of variables (bath ankylosing spondylitis disease activity index) an appropriate instrument? Rheumatology (Oxford) 1999; 38(9):878–882.

    Article  CAS  Google Scholar 

  37. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62(9):817–824.

    Article  PubMed  CAS  Google Scholar 

  38. Anderson JJ, Baron G, van der Heijde D et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44(8):1876–1886.

    Article  PubMed  CAS  Google Scholar 

  39. Dougados M, Behier JM, Jolchine I et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44(1):180–185.

    Article  PubMed  CAS  Google Scholar 

  40. Dougados M, Nguyen M, Caporal R et al. Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 1994; 23(5):243–248.

    Article  PubMed  CAS  Google Scholar 

  41. Dougados M, Caporal R, Doury P et al. A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 1989; 16(8):1167–1169.

    PubMed  CAS  Google Scholar 

  42. Dougados M, Gueguen A, Nakache JP et al. Ankylosing spondylitis: What is the optimum duration of a clinical study? A one year versus a 6 weeks nonsteroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999; 38(3):235–244.

    Article  CAS  Google Scholar 

  43. Braun J, Davis J, Dougados M et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006; 65(3):316–320.

    Article  PubMed  CAS  Google Scholar 

  44. Gladman DD, Mease PJ, Strand V et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007; 34(5):1167–1170.

    PubMed  Google Scholar 

  45. Fredriksson T, Pettersson U. Severe psoriasis — Oral therapy with a new retinoid. Dermatologica 1978; 157(4):238–244.

    Article  PubMed  CAS  Google Scholar 

  46. Ashcroft DM, Wan Po AL, Williams HC et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141(2):185–191.

    Article  PubMed  CAS  Google Scholar 

  47. Anderson RT, Aaronson NK, Wilkin D. Critical review of the international assessments of health-related quality of life. Qual Life Res 1993; 2(6):369–395.

    Article  PubMed  CAS  Google Scholar 

  48. Brazier J, Jones N, Kind P. Testing the validity of the Europol and comparing it with the SF-36 health survey questionnaire. Qual Life Res 1993; 2(3):169–180.

    Article  PubMed  CAS  Google Scholar 

  49. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) — A simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19(3):210–216.

    Article  PubMed  CAS  Google Scholar 

  50. Chren MM, Lasek RJ, Flocke SA et al. Improved discriminative and evaluative capability of a refined version of skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133(11):1433–1440.

    Article  PubMed  CAS  Google Scholar 

  51. Mease PJ, Antoni CE, Gladman DD et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005; 64(Suppl 2):ii49–54.

    Article  PubMed  Google Scholar 

  52. Felson DT, Anderson JJ, Boers M et al. American college of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6):727–735.

    Article  PubMed  CAS  Google Scholar 

  53. Clegg DO, Reda DJ, Mejias E et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 1996; 39(12):2013–2020.

    Article  PubMed  CAS  Google Scholar 

  54. van Gestel AM, Prevoo ML, van’t Hof MA et al. Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American college of rheumatology and the world health organization/international league against rheumatism criteria. Arthritis Rheum 1996; 39(1):34–40.

    Article  PubMed  Google Scholar 

  55. Fransen J, Antoni C, Mease PJ et al. Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006; 65(10):1373–1378.

    Article  PubMed  CAS  Google Scholar 

  56. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52(4):1227–1236.

    Article  PubMed  CAS  Google Scholar 

  57. Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64(8):1150–1157.

    Article  PubMed  CAS  Google Scholar 

  58. Brockbank JE, Stein M, Schentag CT et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis 2005; 64(2):188–190.

    Article  PubMed  CAS  Google Scholar 

  59. Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: Which is the best instrument to use? J Rheumatol 2007; 34(6):1302–1306.

    PubMed  Google Scholar 

  60. Helliwell PS, Firth J, Ibrahim GH et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005; 32(9):1745–1750.

    PubMed  Google Scholar 

  61. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000; 25(5):357–362.

    Article  PubMed  Google Scholar 

  62. de Jong EM, Seegers BA, Gulinck MK et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193(4):300–303.

    Article  PubMed  Google Scholar 

  63. Rich P, Scher RK. Nail psoriasis severity index: A useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49(2):206–212.

    Article  PubMed  Google Scholar 

  64. Aktan S, Ilknur T, Akin C et al. Interobserver reliability of the nail psoriasis severity index. Clin Exp Dermatol 2007; 32(2):141–144.

    Article  PubMed  CAS  Google Scholar 

  65. Parrish CA, Sobera JO, Elewski BE. Modification of the nail psoriasis severity index. J Am Acad Dermatol 2005; 53(4):745–746; author reply 746–747.

    Article  PubMed  Google Scholar 

  66. Cassell SE, Bieber JD, Rich P et al. The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007; 34(1):123–129.

    PubMed  Google Scholar 

  67. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52(10):3279–3289.

    Article  PubMed  CAS  Google Scholar 

  68. Chandran V, Bhella S, Schentag C et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007; 66(7):936–939.

    Article  PubMed  Google Scholar 

  69. Gladman DD, Brubacher B, Buskila D et al. Differences in the expression of spondyloarthropathy: a comparison between ankylosing spondylitis and psoriatic arthritis. Clin Invest Med 1993; 16(1):1–7.

    PubMed  CAS  Google Scholar 

  70. Husted JA, Gladman DD, Cook RJ et al. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998; 25(11):2146–2155.

    PubMed  CAS  Google Scholar 

  71. Husted JA, Gladman DD, Farewell VT et al. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997; 24(3):511–517.

    PubMed  CAS  Google Scholar 

  72. McKenna SP, Doward LC, Whalley D et al. Development of the PsA QoL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 2004; 63(2):162–169.

    Article  PubMed  CAS  Google Scholar 

  73. McEwen C, DiTata D, Lingg C et al. Ankylosing spondylitis and spondylitis accompanying ulcerative colitis, regional enteritis, psoriasis and Reiter’s disease. A comparative study. Arthritis Rheum 1971; 14(3):291–318.

    Article  PubMed  CAS  Google Scholar 

  74. Helliwell PS, Hickling P, Wright V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis and reactive arthritis? Ann Rheum Dis 1998; 57(3):135–140.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, University Hospital Ghent, De Pintelaan 185, 9000, Ghent, Belgium

    Ruth Wittoek & Herman Mielants

Authors
  1. Ruth Wittoek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Herman Mielants
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital Universitario Central de Asturias, Oviedo, Spain

    Carlos López-Larrea PhD  & Roberto Díaz-Peña BSc  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Landes Bioscience and Springer Science+Business Media

About this chapter

Cite this chapter

Wittoek, R., Mielants, H. (2009). Clinical Assessment in the Spondyloarthropathies. In: López-Larrea, C., Díaz-Peña, R. (eds) Molecular Mechanisms of Spondyloarthropathies. Advances in Experimental Medicine and Biology, vol 649. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0298-6_1

Download citation

Publish with us

Policies and ethics

Search

Navigation